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Background: Lung cancer is one of the leading causes of cancer death worldwide. Even with complete resection,
the prognosis of early-stage non-small cell lung cancer is poor due to local and distant recurrence, and it remains
unclear which biomarkers are clinically useful for predicting recurrence or for determining the efficacy of
chemotherapy. Recently, several lines of evidence have indicated that the enzymatic activity of cyclin-dependent
kinases could be a clinically relevant prognostic marker for some cancers. We investigated whether the specific
activity of cyclin-dependent kinases 1 and 2 could predict recurrence or death in early non-small cell lung cancer
patients.
Methods: Patients with newly diagnosed, pathologically confirmed non-small cell lung cancer were entered into
this blinded cohort study. The activity of cyclin-dependent kinases was determined in 171 samples by the C2P®
assay, and the results were subjected to statistical analysis with recurrence or death as a clinical outcome.
Results: The Cox proportional hazards model revealed that the activity of cyclin-dependent kinase 1, but not 2, was
a predictor of recurrence, independent of sex, age, and stage. By contrast, cyclin-dependent kinase 2 activity was a
predictor of death, independent of sex and stage.
Conclusion: This study suggested the possible clinical use of cyclin-dependent kinase 1 as a predictor of recurrence
and cyclin-dependent kinase 2 as a predictor of overall survival in early-stage non-small cell lung cancer. Thus, a
combination of activity of cyclin-dependent kinases 1 and 2 is useful in decision-making regarding treatment
strategies for non-small cell lung cancer after surgery.
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Lung cancer is one of the leading causes of cancer death
worldwide. Despite recent advances in cancer treatment,
the prognosis of lung cancer is not sufficient compared
with that of other solid organ tumors [1]. Even after
complete surgical resection, the 5-year survival of early-
stage non-small cell lung cancer (NSCLC) patients is only
approximately 65% [2-4]. This poor prognosis is due to the
high recurrence after resection [5,6], which supports the* Correspondence: hkubo@med.tohoku.ac.jp
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unless otherwise stated.presence of occult metastases. The survival benefit of ad-
juvant platinum-based chemotherapy has been established
in stage II–III NSCLC [7-9]; however, there is no data
supporting the use of adjuvant treatments for stage IA
NSCLC, and the use of adjuvant chemotherapy for stage
IB NSCLC is controversial [10]. Recently developed mo-
lecular biomarkers predict only non-squamous NSCLC
[11,12], and no biomarkers for squamous cell carcinoma
(SCC) have reached the validation stage. Therefore, in the
setting of lung cancer, the identification of biomarkers for
predicting the outcome after surgery and selecting pa-
tients who could benefit from adjuvant chemotherapy is
crucial.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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http://www.biomedcentral.com/1471-2407/14/755A breakdown in the cell cycle machinery induces the
uncontrolled proliferation of tumors. This process is initi-
ated by a variety of molecules in a cascade that activates
the cyclin-dependent kinases (CDKs), which play a role in
the progression of the cell cycle. On the molecular level,
the activity of CDKs is regulated by subunits known as
cyclins, and by phosphorylation and dephosphorylation of
key residues, for example, Thr14, Tyr15, and Thr160 in
CDK2 [13]. A series of pathological investigations of the
molecules that stimulate CDKs have clearly demonstrated
their clinical significance for cancer diagnosis and treat-
ment. For example, clinical evidence has indicated that
the overexpression of cyclin E and cyclin B, which bind to
and activate CDK2 and CDK1, respectively, correlates
with tumorigenesis, prognosis, and sensitivity to chemo-
therapy in a variety of malignancies, as does the inactiva-
tion of CDK inhibitors, such as p21WAF1 and p27Kip1
[14-20]. The pairing between the CDK and cyclin isotypes
is specific. However, the amount of cyclin protein did not
correspond perfectly with CDK activity in our investiga-
tion (data not shown). Similar results regarding the associ-
ation between cyclin E and the activity of its associated
kinase were reported by another group [21]. Therefore, we
hypothesized that the direct measurement of CDK activity
might produce relevant clinical indications for cancer
diagnosis and treatment. Previously, we reported that the
CDK-based risk score (C2P® assay, Sysmex, Japan) pre-
dicted the risk of distant recurrence in early breast cancer
patients [22]. The C2P® assay is determined using a com-
bination of the specific activity of CDK1 (CDK1SA) and
CDK2 (CDK2SA). The feasibility of this assay was con-
firmed in a cohort study in Caucasian breast cancer pa-
tients [23] and in colon cancer patients [24]. CDKSAs
were also significantly associated with a pathologically
complete response (pCR) after weekly administration of
paclitaxel followed by 5-fluorouracil, epirubicin, and
cyclophosphamide in breast cancer [25].
In lung cancer, many cell cycle-related molecules have
been reported to be correlated with prognosis [26-31].
Here, we investigated whether the activity of CDK1 and
CDK2 could predict the recurrence of NSCLC or the
death of stage I and II NSCLC patients.
Methods
Study design
This blinded cohort study was approved by the local ethics
committees of Tohoku University and Hyogo Cancer
Centre. All patients provided written informed consent. A
total of 213 patients who were newly diagnosed with patho-
logically confirmed NSCLC at the two centers were
enrolled in this study. The eligibility criteria were as follows:
SCC, adenocarcinoma, and stage I–II disease. All patients
underwent complete resection, and none received adjuvant
or neoadjuvant chemotherapy. CDK1SA and CDK2SAwere determined in 171 samples using a C2P® assay
(Sysmex, Kobe, Japan), and the results were subjected to
statistical analysis to evaluate recurrence or death as a clin-
ical outcome. Tumor tissue was dissected immediately after
resection, snap-frozen and stored at −80°C at each facility.
Then, the samples were sent to the Sysmex Corporation
(Kobe, Japan) and subjected to the C2P® assay. Tissues with
extreme blood contamination were excluded from this
study, because the expression level of CDKs is underesti-
mated in the presence of more than 1600 ng/μL of
hemoglobin. The histologic types were centrally reviewed
at Tohoku University.
Patients
A total of 213 patients with primary NSCLC who had
undergone surgery between July 2000 and September
2009 were recruited for this study. Twenty-four cases
were excluded due to extreme blood contamination of
the samples. C2P® assay measurements were performed
on 189 frozen samples; in 18 cases, the CDK expression
levels were below the detection threshold, and these
samples were excluded from the analysis. Finally, 171
cases were subjected to statistical analyses, including 53
SCCs and 118 adenocarcinomas. The median follow-up
period was 43.9 months (70–2820 days).
Measurement of CDK1SA and CDK2SA
The C2P® assay [15,22] was used to measure the specific
activity of CDKs. In brief, lysates of freshly frozen
samples were applied to the wells of a 96-well PVDF fil-
ter plate (Millipore, Billerica, MD, USA). The expression
of CDK protein was detected quantitatively by sequen-
tial reactions with primary anti-CDK antibodies, bio-
tinylated anti-rabbit antibodies and fluorescein-labeled
streptavidin. To measure the kinase activity, CDK mole-
cules were immunoprecipitated from the lysate using
protein beads. CDK SA activity (maU/eU) was calcu-
lated as CDK activity units (maU/μL lysate), which were
divided by their corresponding CDK expression units
(eU/μL lysate). maU (CDK activity unit) and eU (CDK
expression unit) were defined as the enzyme activity
and expression equivalent to 1 ng of recombinant kin-
ase, respectively. When the expression level was lower
than the detection limit of the assay, the case was ex-
cluded from the analysis. The detection limits for the
expression level of CDK1 and CDK2 are 0.1 and 0.003
eU/μL lysate, respectively.
Statistical analysis
Recurrence-free survival (RFS) was calculated from the date
of surgery to the date of first local or distant recurrence; pa-
tients who were alive without recurrence at the time of data
collection and those who died without any evidence of the
disease on the date of death were censored. The overall
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date of death; patients who were alive were censored.
The data were analyzed using MedCalc version 12.3
(MedCalc Software, Ostend, Belgium), and survival be-
tween the groups was compared using the Kaplan-Meier
method and an unstratified Cox proportional hazards
model or the log-rank test. Correlation tables were ana-
lyzed using the chi-square test. Receiver operating charac-
teristic (ROC) curves and the corresponding area under
the curve (AUC) for the compared models were computed
to simulate predictive accuracy.
Possible prognostic variables that were analyzed in this
study included age (≥70 vs <70 years), sex (male or fe-
male), tumor size (>3 vs ≤3 cm), nodal status (negative or
positive), pathological stage (≥IB vs IA), histological type
(SCC or adenocarcinoma), CDK1SA (≥12.6 vs <12.6) and
CDK2SA (≥222 vs <222). A value of p <0.05 was consid-
ered significant.
Results
We obtained fresh-frozen samples from 213 cases from
two centers: Tohoku University Hospital and Hyogo
Cancer Centre. Twenty-four cases were excluded due to ex-
treme blood contamination. The C2P® assay was performed
on 189 frozen samples (see Additional file 1); in 18 cases,
the CDK expression levels were below the detection thresh-
old, and these cases were excluded from the analysis (assay
success rate =90%). Finally, 171 samples were subjected to
statistical analysis (Figure 1). The patients who were ana-
lyzed included 106 (62%) males and 65 (38%) females, with
a median age of 70 years (38–86) (Table 1). The median
tumor size was 3.0 cm (0.9–10.0). A total of 150 cases
(88%) were node-negative, and 21 cases (12%) were posi-
tive. The histologic type was centrally confirmed as SCC in
53 cases (31%) and adenocarcinoma in 118 cases (69%).
The overall recurrence rate and overall survival rate at final
follow-up were 22% (local, 8%; distant, 14%) and 78% (133/
171), respectively. Thirty-five out of 37 recurrent cases re-
ceived platinum-based chemotherapy. The distribution of
CDK1SA and CDK2SA did not vary significantly between
the two independent cohorts based on the chi-square test
(p =0.2102 and p =0.3557, respectively; Table 2). ToFigure 1 Flow chart of patient enrolment and reasons for exclusion.examine the prognostic significance of the CDK1SA and
CDK2SA results, ROC analysis was performed with overall
recurrence as a clinical outcome.
The area under the ROC curves (AUC) of CDK1SA
(p =0.0498) and CDK2SA (p =0.4206) were 0.607 and
0.545, respectively, which indicated that CDK1SA, but
not CDK2SA, was likely to be predictive of recurrence.
The analysis revealed that the Youden Indexes for
CDK1SA and CDK2SA were maximized at 12.6 maU/eU
and 222 maU/eU, respectively. Therefore, these values
were tentatively set as the cut-off points in this study.
Coincidentally, the optimal cut-off value of lung cancer
approximated that of our colon study (11 maU/eU) [24].
The correlation analyses between CDKSA and the clini-
copathologic parameters revealed that none of the pa-
rameters was associated with CDK1SA, while CDK2SA
was significantly correlated with stage (p =0.0267) and
histology (p <0.0001) (Table 2).
With a cut-off value of 12.6 maU/eU, the cases were
classified as low CDK1SA (54%, 92 cases) or high
CDK1SA (46%, 79 cases). In the Kaplan-Meier analysis,
patients with low CDK1SA tumors showed significantly
higher RFS than those with high CDK1SA tumors based
on a log-rank test (Figure 2A, HR 2.26, 95% CI 1.18–
4.32; p =0.0147); however, no prognostic value was ob-
served (Figure 2B, p =0.0921).
CDK1SA and conventional clinicopathologic parame-
ters, including sex (male vs female), age (<70 vs ≥70),
tumor size (≤3 cm vs >3 cm), pathological lymph node
status (positive vs negative), clinical stage (IA vs IB-IIB),
and histology (SCC vs adenocarcinoma) were analyzed
using a Cox proportional hazards model with recurrence
or death as a clinical outcome (Tables 3 and 4). Univari-
ate analysis for recurrence revealed that sex (HR 2.53,
95% CI 1.16–5.52; p =0.0200), age (HR 2.80, 95% CI
1.36–5.77; p =0.0054), tumor size (HR 1.99, 95% CI
1.04–3.81; p =0.0380), pathological lymph node status
(HR 3.20, 95% CI 1.51–6.77; p =0.0025), stage (HR 2.54,
95% CI 1.30–4.99; p =0.0070) and CDK1SA (HR 2.26,
95% CI 1.16–4.43; p =0.0177) were statistically signifi-
cant (p <0.05). Age, stage and CDK1SA remained signifi-
cant by multivariate analysis for recurrence (Table 3, age
Table 1 Clinical and pathological characteristics of patients
Total collective Tohoku University Hyogo Cancer Centre
Frozen blocks available 213 111 102
Successful CDK assay 171 90 81
Sex Male 106 (62%) 57 (63%) 49 (60%)
Female 65 (38%) 33 (37%) 32 (40%)
Age < 70 years 83 (49%) 43 (48%) 40 (49%)
≥ 70 years 88 (52%) 47 (52%) 41 (51%)
Tumor size ≤ 3 cm 95 (56%) 52 (58%) 43 (53%)
> 3 cm 76 (44%) 38 (42%) 38 (47%)
pN − 150 (88%) 83 (92%) 67 (83%)
+ 21 (12%) 7 (8%) 14 (17%)
Stage IA 89 (52%) 48 (53%) 41 (51%)
IB 45 (26%) 28 (31%) 17 (21%)
IIA 31 (18%) 11 (12%) 20 (25%)
IIB 6 (4%) 3 (3%) 3 (4%)
Histology Adenocarcinoma 118 (69%) 58 (64%) 60 (74%)
SCC 53 (31%) 32 (36%) 21 (26%)
Recurrence None 134 (78%) 81 (90%) 53 (65%)
Local 14 (8%) 3 (3%) 11 (14%)
Distant 23 (14%) 6 (7%) 17 (21%)
Survival information Alive 133 (78%) 75 (83%) 58 (72%)
Dead 38 (22%) 15 (17%) 23 (28%)
Table 2 Association between CDK-based risk groups and clinicopathological parameters
CDK1SA (cut-off = 12.6) CDK2SA (cut-off = 222)
Low High Significance (Chi-square) Low High Significance (Chi-square)
Sex Male 57 49 76 30
Female 35 30 p =0.8817 55 10 p =0.0800
Age < 70 years 43 40 66 17
≥ 70 years 49 39 p =0.7230 65 23 p =0.4888
Tumor size ≤ 3 cm 55 40 76 19
> 3 cm 37 39 p =0.2955 55 21 p =0.3223
pN − 85 65 118 32
+ 7 14 p =0.0759 13 8 p =0.1544
Stage IA 53 36 73 16
IB 25 20 37 8
IIA 12 19 18 13
IIB 2 4 p =0.1652 3 3 p =0.0267
Histology Adenocarcinoma 64 54 101 17
SCC 28 25 p =0.9961 30 23 p <0.0001
Facility Tohoku Univ 53 37 72 18
Hyogo CC 39 42 p =0.2102 59 22 p =0.3557
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Figure 2 Analysis of recurrence and survival by risk category. (A) Recurrence-free survival and (B) overall survival according to CDK1SA-based risk
with a cut-off value of 12.6 maU/eU. (C) Recurrence- free survival and (D) overall survival according to CDK2SA-based risk with a cut-off value of
222 maU/eU.
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HR 2.25, p =0.0195). Even in the subgroup of 134 patients
with stage IA and IB disease, CDK1SA but not CDK2SA
had the prognostic power (Figures 3A and B, CDK1SA
HR 2.56, p =0.0273; CDK2SA HR 1.18, p =0.7375). The
Cox regression analysis revealed that CDK1SA was an in-
dependent predictor of recurrence (Table 5, HR 2.57, 95%
CI 1.08–6.09; p =0.0335).
Regarding CDK2SA, which had a cut-off value of 222
maU/eU, the cases were classified as low CDK2SA (77%,
131 cases) or high CDK2SA (23%, 40 cases). Patients with
low CDK2SA tumors showed significantly higher OS thanTable 3 Cox proportional hazards models for recurrence
Univariate analysis
HR (95% CI) p value
Sex Male 2.53 (1.16–5.52) 0.0200
Age ≥ 70 years 2.80 (1.36–5.77) 0.0054
Tumor size > 3 cm 1.99 (1.04–3.81) 0.0380
pN + 3.20 (1.51–6.77) 0.0025
Stage ≥ IB 2.54 (1.30–4.99) 0.0070
Histology SCC 1.23 (0.62–2.44) 0.5567
CDK1SA ≥ 12.6 2.26 (1.16–4.43) 0.0177
CDK2SA ≥ 222 1.82 (0.93–3.56) 0.0837those with high CDK2SA tumors based on a log-rank test
(Figure 2D, HR 2.49, 95% CI 1.19–5.21; p =0.0033).
According to the univariate analysis for death,
CDK2SA (HR 2.56, 95% CI 1.34–4.87; p =0.0045) was
statistically significant along with sex (HR 5.51, 95% CI
1.96–15.5; p =0.0013), tumor size (HR 2.36, 95% CI
1.22–4.55, p =0.0111), pathological lymph node status
(HR 2.82, 95% CI 1.34–5.96; p =0.0069) and stage (HR
2.75, 95% CI 1.39–5.44; p =0.0039). By multivariate ana-
lysis, sex, stage, and CDK2SA remained significant (sex
HR 4.14, p =0.0081; stage HR 2.09, p =0.0421; CDK2SA
HR 1.97, p =0.0500).Multivariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
1.99 (0.90–4.42) 0.0913 2.00 (0.91–4.40) 0.0876
3.06 (1.48–6.34) 0.0028 2.79 (1.35–5.75) 0.0056
2.16 (1.08–4.31) 0.0306 2.23 (1.13–4.43) 0.0222
2.25 (1.14–4.42) 0.0195
1.53 (0.79–3.01) 0.2165
Table 4 Cox proportional hazards models for death
Univariate analysis Multivariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Sex Male 5.51 (1.96–15.46) 0.0013 4.29 (1.50–12.30) 0.0070 4.14 (1.45–11.78) 0.0081
Age ≥ 70 years 1.24 (0.66–2.35) 0.5088
Tumor size > 3 cm 2.36 (1.22–4.55) 0.0111
pN + 2.82 (1.34–5.96) 0.0069
Stage ≥ IB 2.75 (1.39–5.44) 0.0039 1.79 (0.87–3.71) 0.1174 2.09 (1.03–4.24) 0.0421
Histology SCC 2.49 (1.31–4.72) 0.0053 1.53 (0.78–2.97) 0.2156 1.23 (0.62–2.47) 0.5555
CDK1SA ≥ 12.6 1.74 (0.91–3.32) 0.0962 1.53 (0.79–2.97) 0.2122
CDK2SA ≥ 222 2.56 (1.34–4.87) 0.0045 1.97 (1.00–3.87) 0.0500
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value of CDK1SA for recurrence was stronger in adeno-
carcinoma than in SCC (Figure 4A and B, adenocarcin-
oma HR 2.26, p =0.0439; SCC HR 2.09, p =0.2182). On
the contrary, in the SCC cases, the Cox regression ana-
lysis for recurrence revealed that only CDK2SA was sta-
tistically significant (Figure 4C and D, Table 6, HR 3.86,
95% CI 1.05–14.2; p =0.0428).
In the distribution of 35 recurrent cases on a scatter
diagram with logarithmic scales according to CDK1SA
and CDK2SA, we observed that the distribution of the
non-survivors slightly shifted to the higher CDKSAs area
(data not shown). This observation let us to perform
Kaplan-Meier analyses, and it was found that the prog-
nostic power of CDK2SA, but not of CDK1SA
(Figure 5A), was significant in 35 patients who were
treated with chemotherapy after recurrence (Figure 5B,
HR for death 4.30, 95% CI 1.56–11.8; p <0.0001).
Discussion
In this study, we demonstrated that CDK1SA and
CDK2SA could identify individuals that were at high risk
for recurrence and death among early-stage NSCLC pa-
tients after surgical resection. Even with complete resec-
tion, the prognosis of early-stage NSCLC is not goodFigure 3 Analysis of recurrence by risk category in stage I NSCLC. (A)
value of 12.6 maU/eU. (B) Recurrence-free survival according to CDK2SA-badue to local and distant recurrence [6], and it remains
unclear which biomarkers are clinically useful for pre-
dicting recurrence, although some single molecules and
gene signatures of non-squamous cell carcinomas are
being validated in a large number of cohorts [11,32].
Previously, cyclin expression and prognosis were re-
ported to be correlated in lung cancer patients [33];
however, this is the first study revealing that CDK activ-
ity is a promising predictor for early-stage NSCLCs. Fur-
thermore, CDK1SA and CDK2SA are the first
biomarkers that can be used to predict the prognosis of
both adenocarcinoma and SCC. Because CDKs are the
targets of new anti-cancer drugs and the development of
many CDK inhibitors is underway [34], this study will
provide a basis for future personalized medicine using
CDK inhibitors in NSCLC patients.
CDK1SA and CDK2SA have different implications in
lung cancer. CDK1SA predicted recurrence after surgery,
whereas CDK2SA predicted the overall survival of stage
I and II NSCLC patients (Figure 2). Sub-analysis of 134
patients with stage IA and IB disease showed that
CDK1SA was an independent predictor only for recur-
rence, but the power of prediction was much better than
conventional criteria such as tumor size and stage
(Figure 3 and Table 5). The clinical relevance ofRecurrence-free survival according to CDK1SA-based risk with a cut-off
sed risk with a cut-off value of 222 maU/eU.
Table 5 Cox proportional hazards models for recurrence
(Stage I)
Univariate analysis
HR (95% CI) p value
Sex Male 2.17 (0.85–5.53) 0.1050
Age ≥ 70 years 1.79 (0.75–4.24) 0.1908
Tumor size > 3 cm 1.41 (0.59–3.35) 0.4413
Stage ≥ IB 1.67 (0.71–3.90) 0.2390
Histology SCC 1.10 (0.41–2.96) 0.8568
CDK1SA ≥ 12.6 2.57 (1.08–6.09) 0.0335
CDK2SA ≥ 222 1.19 (0.44–3.21) 0.7381
Table 6 Cox proportional hazards models for recurrence
(SCC)
Univariate analysis
HR (95% CI) p value
Sex Male NA
Age ≥70 years 1.48 (0.47–4.65) 0.5014
Tumor size >3 cm 1.77 (0.48–6.52) 0.3905
pN + 1.94 (0.59–6.44) 0.2793
Stage ≥IB 2.42 (0.54–10.99) 0.2530
CDK1SA ≥12.6 2.09 (0.63–6.91) 0.2286
CDK2SA ≥222 3.86 (1.05–14.17) 0.0428
NA, not analyzed due to bias (89% of SCC patients were male).
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agreement with the conclusion of the colon study [24].
In this colon study, CDK1SA was significantly elevated
in microsatellite-stable tumors. Because most of colorec-
tal cancers with stable microsatellites demonstrate
chromosomal instability [35], CDK1SA may have value
as a marker of genomic instability. Genomic instability
has been reported to predict clinical outcomes in mul-
tiple cancer types, including lung cancer [36-39]; there-
fore, prediction of recurrence demonstrated in this study
may reflect the genomic instability of the tumors. Ac-
cording to sub-analysis by histology, the predictive valueFigure 4 Analysis of recurrence by risk category in adenocarcinoma (
CDK1SA-based risk with a cut-off value of 12.6 maU/eU. (C)(D) Recurrence-
222 maU/eU.of CDK1SA for recurrence was greater in adenocarcin-
oma than in SCC (Figure 4A and B). Since adenocarcin-
oma is the most common histologic type of colon
cancer, there is a similarity in the role of CDK1SA in
colon and lung adenocarcinoma. Interestingly, Cox re-
gression analysis for recurrence revealed that CDK2SA
expression was statistically significant in SCC but not in
adenocarcinoma (Figure 4C, D and Table 6). This result
suggests that CDK1 and CDK2 have different roles in
adenocarcinoma and SCC.
In contrast to CDK1SA, CDK2SA predicted overall
survival after surgery. This finding may be related to theA) (C) and SCC (B) (D). (A)(B) Recurrence-free survival according to
free survival according to CDK2SA-based risk with a cut-off value of
Figure 5 Analysis of survival by risk category in recurrent cases. The zero timepoint indicates the diagnosis of recurrence. (A) Survival
according to CDK1SA-based risk with a cut-off value of 12.6 maU/eU. (B) Survival according to CDK2SA-based risk with a cut-off value of
222 maU/eU.
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http://www.biomedcentral.com/1471-2407/14/755chemo-sensitivity of the patients. Kaplan-Meier analysis
indicated that the prognostic power of CDK2SA was
significant in patients treated primarily with platinum-
based chemotherapy after recurrence (Figure 5), sug-
gesting that CDK2SA can predict platinum sensitivity/
resistance. A similar trend was observed in our ovary
study: tumors with high CDK2SA were more platinum-
resistant in patients who underwent incomplete resec-
tion and subsequent platinum-based chemotherapy (un-
published data). The ability of cyclin E-associated kinase
activity to predict the response to platinum-based
chemotherapy in ovarian cancer patients was also re-
ported by another group [21]. In addition, inhibition of
CDK2, but not CDK1, induced growth arrest in lung
cancer cell lines through anaphase catastrophe [40].
Taken together, these data indicate that CDK2 would be
a good target for lung cancer treatment, and the meas-
urement of CDK2SA could be useful for identifying pa-
tients who would receive the full benefit of CDK2
inhibitors.
A limitation of this study was that the number of
cases in the sub-analysis for the outcome after
platinum-based chemotherapy was low; however, the
significant difference was quite clear (Figure 5). Pro-
spective studies should be performed to clarify the pre-
dictive capacity of CDK2SA in platinum sensitivity/
resistance in early-stage NSCLC patients after surgical
resection.
In summary, this study suggested the possible clinical
use of CDK1SA for recurrence prediction and CDK2SA
for the prognosis of stage I and II NSCLC. Moreover,
CDK2SA might be a predictor of platinum-based chemo-
therapy sensitivity/resistance. To the best of our know-
ledge, this is the first report that suggests a relationship
between chemosensitivity and CDK activity in lung can-
cer. Thus, a combination of CDK1SA and CDK2SA might
be helpful in decision-making regarding NSCLC treat-
ment strategies.Conclusions
CDK1SA is a predictor of recurrence and CDK2SA is a
predictor of overall survival in early-stage NSCLC after
surgery.Additional file
Additional file 1: Distribution of lung tumors according to CDK1SA
and CDK2SA. Adenocarcinoma cases and SCC cases are plotted on a
scatter diagram with logarithmic scales according to CDK1SA and
CDK2SA. Black square; the specific activity was defined as 0.5 when the
activity of CDK is lower than the detection limit of the assay. The
detection limits for the activity of CDK1 and CDK2 are 10 and 2 maU/μL
lysate, respectively.Abbreviations
NSCLC: Non-small cell lung cancer; SCC: Squamous cell carcinoma;
CDKs: Cyclin-dependent kinases; CDK1SA: Specific activity of CDK1;
CDK2SA: Specific activity of CDK2.
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